Humanigen Inc (fka HGENQ)

[cowtown jay]

"Safe COVID-19 vaccines for Europeans

Company.... Type of vaccine.... Number of doses (needed per person).... Number of doses (secured)....Status
BioNTech and Pfizer mRNA 2 doses 2.4 billion* Approved
Moderna mRNA 2 doses 460 million Approved
AstraZeneca adenovirus 2 doses 400 million Approved
Johnson & Johnson/Janssen Pharmaceuticals adenovirus 1 dose 400 million Approved
Sanofi-GSK protein 2 doses 300 million Approved
HIPRA Human Health protein 1 dose 250 million Approved
Novavax protein 2 doses 200 million** Approved
Valneva inactivated virus vaccine 1.2 million Approved
*option to purchase 900 million doses, **option to purchase 100 million doses"

"EU grants full marketing authorisation for Novavax’s Covid-19 vaccine
The EMA has granted Novavax’s Covid-19 vaccine a full marketing authorisation, based on Phase III trial data"

.https://www.pharmaceutical-technology.com/news/eu-grants-full-marketing-authorisation-novavax-covid-19-vaccine/

Akosua Mireku
July 7, 2023"

https://commission.europa.eu/strategy-and-policy/coronavirus-response/safe-covid-19-vaccines-europeans_en

"EU delays approval of Novavax's revised COVID vaccine
Reuters
October 15, 202311:36 AM CDTUpdated 14 days ago

The Financial Times, which first reported the news, said the EMA had questions on the potency of the vaccine's latest version, and that it is seeking to ensure its characteristics will be the same across different production sites...EMA director Emer Cooke said in September that it expected to decide on the use of the vaccine this month. The agency is expected to give its approval within four weeks, according to the FT report."

https://www.reuters.com/business/healthcare-pharmaceuticals/eu-delays-approval-novavaxs-revised-covid-vaccine-ft-2023-10-15/

Much greater acceptance of traditional covid vaccines in Europe than in the US and UK. Evidently, the EU is surprised by the reported efficacy data. Might that be due to the use of lenz as an adjuvant? And this doesn't include any discussion of an opportunity with Janssen.